Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.

[1]  L. Gordon,et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. López-Guillermo,et al.  The clinical significance of molecular response in indolent follicular lymphomas. , 1998, Blood.

[4]  A. Demidem,et al.  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.

[5]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[6]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[7]  A. Iavarone,et al.  Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance. , 1995, Cancer research.

[8]  S. Bianchi,et al.  Bcl-2 overexpression and smoking history in head and neck cancer. , 1995, Journal of the National Cancer Institute.

[9]  S. Steinberg,et al.  Sequential analysis of 43 patients with non-Hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies. , 1995, Blood.

[10]  C. Croce,et al.  Purification and characterization of the bcl-2 protein. , 1994, Archives of biochemistry and biophysics.

[11]  U. Jäger,et al.  Karyotype and prognosis in non-Hodgkin lymphoma. , 1994, Leukemia.

[12]  Annick,et al.  Prognostic value of chromosomal abnormalities in follicular lymphoma. , 1994, Blood.

[13]  J. Gribben,et al.  Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow , 1994 .

[14]  U. Veronesi,et al.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.

[15]  P. Ramani,et al.  Expression of bcl‐2 gene product in neuroblastoma , 1994, The Journal of pathology.

[16]  L. Ding,et al.  Developmental regulation of the Bcl‐2 protein and susceptibility to cell death in B lymphocytes. , 1994, The EMBO journal.

[17]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[18]  John Calvin Reed,et al.  Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.

[19]  J. Gribben,et al.  Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. , 1993, Blood.

[20]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[21]  J. Gribben,et al.  All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.

[22]  D. Mason,et al.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. , 1990, The American journal of pathology.

[23]  C. Croce,et al.  DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. R. Howe,et al.  Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. , 1982, The New England journal of medicine.

[25]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .